Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zidovudine + Lamivudine in HAM/TSP
NCT00272480Phase 3Completed
- Sponsor
- Imperial College London
- Start
- Nov 1999
- Primary completion
- Jul 2002
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in HTLV-I associated myelopathy (HAM/TSP) comparing Placebo with Zidovudine + Lamivudine (2 arms). Primary endpoints: Timed walk at 6 months, Osame's Motor Disability Score at 6 months and 3 more. Started Nov 1999; status: completed.
02
Drugs
zidovudinelamivudine
03
Conditions
HTLV-I associated myelopathy (HAM/TSP)
Beyond the preview
Go deeper on NCT00272480.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00272480.